Solide Tumoren - Leber, Galle, Pankreas - Karzinome des exokrinen Pankreas -

Weiterführende Informationen

Leitlinien

S3-Leitlinie der DKG: www.krebsgesellschaft.de → Leitlinien (10/2006)

www.dgho-onkopedia.de → Leitlinien (Oettle et al. 02/2010)

Studien

www.studien.de (DKG), www.eortc.be (EORTC), www.clinicaltrials.gov (NIH/USA)

Literatur

1. Chang BW et al: Locally advanced pancreatic adenocarcinoma: where are we and where are we going? J Pancreas 2011; 12: 101–5
2. Chauffert et al: Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol 2008; 19: 1592–99
3. Ghaneh P et al: Biology and management of pancreatic cancer. Gut 2007; 56: 1134–52
4. Gillen S et al: Palliative resections versus palliative bypass procedures in pancreatic cancer-a systematic review. Am J Surg. 2011 Aug 25; (Epub ahead of print)
5. Ioka T et al: A randomized phase II study of gemcitabine 1000mg/msq and concurrent radiotherapy comparing gemcitabine alone for unresectable locally advanced pancreatic adenocarcinoma.  Int J Radiat Oncol Biol Phys 2010; 78: 3 (suppl) 102
6. Jingu K etal: Results of intraoperative radiotherapy for pancreatic cancer in the last decade: Comparing with historical results. Proc 52nd Annual ASTRO Meeting 2011 #2239
7. Linder S et al: Pancreatic carcinoma incidence and survival in Sweden in 1980–2000: a population-based study of 16.758 hospitalized patients with special reference to different therapies. Eur J Surg Oncol 2007; 33: 616–22
8. Lopez C et al: Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1. Langenbecks Arch Surg. 2011 Jul 30; (Epub ahead of print)
9. Miller RC et al: Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic  for the 5th JUCTS symposium. Int J Radiat Oncol Biol Phys 2009; 75: 364–8
10. Moore JM et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960–6
11. Neoptolemos J et al: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010; 304(10): 1073–81
12. Neuhaus P et al: CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol 2008; 26: (May 20 (suppl) LBA4504
13. Oettle H et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267–77
14. Ogawa K et al.: Intraoperative radiotherapy for unresectable pancreatic cancer: A multi-institutional restrospective analysis of 144 patients. Int J Radiat Oncol Biol Phys 2011; 80: 111–118
15. Pavel M et al: A randomized, double-blind, placebo trial of everolimus + octreotide LAR vs placebo + octreotide LAR in patients with advanced neuroendocrine tumors – controlled, multicenter Phase III (NET) (RADIANT-2). Ann Oncol 2010; 21(suppl 8): viii4, LBA8
16. Raymond E et al: Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. N Engl J Med 2011; 364: 501–13
17. Sultana A et al: Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 2007; 96: 1183–90
18. Conroy T et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364(19): 1817-25
    Yao JC et al: Everolimus for Advanced Pancreatic Neuroendocrine Tumors. N Engl J Med 2011; 364: 514–23